Noxon, a Munich-based MedTech startup focused on non-invasive neuro- and muscle technologies, has closed a multi-million-euro Seed funding round.
The round was led by High-Tech Gründerfonds (HTGF) and Bayern Kapital, with participation from Auxxo and another institutional investor.
“Neurological and musculoskeletal diseases are on the rise globally. Healthy muscle function is fundamental, yet often overlooked, and existing solutions tend to be too complex or costly. The support from HTGF and Bayern Kapital enables us to further validate our platform technology clinically and bring our first products to market. Our goal is to make muscle health transparent, personalised, and affordable for everyone,” said Maria Neugschwender, co-founder and CEO of Noxon.
Founded in 2022, Noxon tackles muscle health challenges with a non-invasive muscle-computer interface. According to the company, in rehabilitation and for neuromuscular disorders, muscle diagnostics and activation are traditionally performed only sporadically and under clinical conditions. This results in patients lacking continuous data and adaptive therapy in their daily lives throughout the treatment process.
Noxon claims to address this gap with a medical muscle-computer Interface that, for the first time, combines continuous muscle diagnostics and neuromuscular electrical stimulation (NMES) in a wearable suitable for everyday use.
“The key innovation lies in the closed feedback loop of real-time measurement and personalised muscle and nerve activation over the course of therapy, seamlessly integrated into existing products such as tapes, patches, and orthopaedic aids,” mentioned the company in the press release.
The company is also collaborating with medical partners, including the University Hospital Würzburg and the neuroscience group N-Squared Lab, on additional pilot applications. These initiatives focus on applications that support muscle control in cases where signal transmission between the brain and muscles is impaired, including solutions that reduce tremor in patients with Parkinson’s disease.
“Noxon’s technology platform, which enables human muscles to be both ‘read’ and then stimulated and activated, holds significant potential across a range of applications, particularly in therapy and medical rehabilitation. Based on this approach, conditions that are currently difficult to treat, such as Parkinson’s or paralysis, could be addressed more effectively and gently for patients. This would represent major value for both medical technology and healthcare as a whole, making Noxon a very promising investment,” said Monika Steger, Managing Director of Bayern Kapital.
The company plans to use the fresh capital to advance the clinical validation and certification of its non-invasive muscle-computer interface and to prepare for the market launch of its first therapy modules.
Read the orginal article: https://www.eu-startups.com/2026/03/munich-based-noxon-closes-seed-funding-to-turn-muscles-into-digital-interfaces-for-neuromuscular-care/
